Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Nat Med. 2019 Nov 7;25(11):1753–1760. doi: 10.1038/s41591-019-0627-8

Table 3. Net Reclassification Index for composite fatal/non-fatal CVD outcome for 3 eGFR measures: eGFRcr, eGFRcys and eGFRcr-cys.

Comparator       Addition Case NRI
(95%CI)		 Non-case NRI
(95% CI)
Atherosclerotic risk factors +eGFRcr -0.08%
(-0.41, +0.22%)		 -0.01%
(-0.03, +0.01%)
Atherosclerotic risk factors +eGFRcys +1.54%
(+1.01, +2.10%)		 -0.17%
(-0.21, -0.14%)
Atherosclerotic risk factors +eGFRcr-cys +1.02%
(+0.53, +1.48%)		 -0.11%
(-0.14, -0.08%)
Atherosclerotic risk factors +eGFRcr +uACR 0.08%
(-0.13, +0.19%)		 +0.01%
(0.00, +0.02%)
Atherosclerotic risk factors +eGFRcys +uACR -0.03%
(-0.15, +0.09%)		 +0.02%
(0.01, +0.03%)
Atherosclerotic risk factors +eGFRcr-cys +uACR 0.07%
(-0.05, +0.18%)		 +0.01%
(0.00, +0.02%)

Estimated glomerular filtration rate (eGFR) method: eGFR based on creatinine (eGFRcr), eGFR based on cystatin C (eGFRcys) and eGFR based on creatinine and cystatin C (eGFRcr-cys). uACR urine albumin:creatinine ratio